Trial Profile
A Phase 2 Randomized Blinded Placebo Controlled Comparison of the Safety Pharmacokinetics and Pharmacodynamics of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs SYN 023 (Primary) ; Rabies immune globulin; Rabies vaccine
- Indications Rabies
- Focus Pharmacodynamics
- Acronyms RabiesMab
- Sponsors Synermore Biologics
- 02 Sep 2021 The study was amended after initiation to allow replacement of subjects who withdrew from the study before Day 28 as per results published in the Vaccine
- 02 Sep 2021 Results published in the Vaccine
- 09 Jan 2018 Status changed from recruiting to completed.